| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 13 | 2024 | 395 | 2.450 |
Why?
|
| Myeloproliferative Disorders | 11 | 2024 | 132 | 2.440 |
Why?
|
| Primary Myelofibrosis | 6 | 2024 | 67 | 2.240 |
Why?
|
| Leukemia, Myeloid, Acute | 18 | 2024 | 788 | 2.130 |
Why?
|
| Myelodysplastic Syndromes | 10 | 2024 | 357 | 2.050 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2017 | 48 | 1.070 |
Why?
|
| MicroRNAs | 8 | 2017 | 551 | 1.010 |
Why?
|
| Gene Expression Regulation, Leukemic | 6 | 2021 | 93 | 0.980 |
Why?
|
| Erythrocytes | 2 | 2020 | 254 | 0.920 |
Why?
|
| Leukemia, B-Cell | 2 | 2022 | 23 | 0.920 |
Why?
|
| Neoplastic Stem Cells | 3 | 2024 | 161 | 0.910 |
Why?
|
| Herpesvirus 4, Human | 2 | 2023 | 119 | 0.910 |
Why?
|
| Oncogene Proteins, Fusion | 4 | 2021 | 133 | 0.810 |
Why?
|
| Neoplasm Proteins | 12 | 2021 | 540 | 0.810 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 3 | 2022 | 29 | 0.800 |
Why?
|
| Mutation | 21 | 2024 | 4132 | 0.760 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2021 | 49 | 0.750 |
Why?
|
| Sarcoma | 1 | 2023 | 220 | 0.750 |
Why?
|
| Erythrocytes, Abnormal | 1 | 2020 | 12 | 0.750 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2020 | 889 | 0.740 |
Why?
|
| Hematologic Neoplasms | 2 | 2023 | 342 | 0.740 |
Why?
|
| Down Syndrome | 6 | 2023 | 55 | 0.730 |
Why?
|
| Hematopoietic Stem Cells | 9 | 2023 | 299 | 0.720 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 7 | 2016 | 72 | 0.700 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 1 | 2019 | 10 | 0.690 |
Why?
|
| Humans | 86 | 2024 | 89063 | 0.650 |
Why?
|
| Megakaryocytes | 6 | 2019 | 36 | 0.630 |
Why?
|
| Anemia, Sickle Cell | 1 | 2020 | 144 | 0.620 |
Why?
|
| RNA Interference | 2 | 2017 | 376 | 0.600 |
Why?
|
| Leukemia, Myeloid | 4 | 2021 | 249 | 0.600 |
Why?
|
| Nuclear Proteins | 6 | 2024 | 726 | 0.580 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2009 | 154 | 0.550 |
Why?
|
| HSP70 Heat-Shock Proteins | 5 | 2003 | 115 | 0.510 |
Why?
|
| Leukemia | 5 | 2022 | 323 | 0.500 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 4 | 2012 | 9 | 0.500 |
Why?
|
| Lymphoma, B-Cell | 3 | 2022 | 106 | 0.490 |
Why?
|
| Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 1 | 2014 | 9 | 0.480 |
Why?
|
| Repressor Proteins | 4 | 2024 | 423 | 0.480 |
Why?
|
| Hematology | 2 | 2020 | 30 | 0.470 |
Why?
|
| Burkitt Lymphoma | 1 | 2014 | 32 | 0.470 |
Why?
|
| Homeodomain Proteins | 7 | 2024 | 556 | 0.470 |
Why?
|
| Hematopoiesis | 3 | 2018 | 165 | 0.460 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2014 | 100 | 0.460 |
Why?
|
| Gene Rearrangement | 5 | 2021 | 172 | 0.450 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2014 | 100 | 0.450 |
Why?
|
| Lymphoma, T-Cell | 4 | 2022 | 55 | 0.450 |
Why?
|
| Bone Marrow | 6 | 2022 | 445 | 0.440 |
Why?
|
| Warts | 1 | 2013 | 11 | 0.440 |
Why?
|
| Histone-Lysine N-Methyltransferase | 6 | 2016 | 161 | 0.430 |
Why?
|
| Agammaglobulinemia | 1 | 2013 | 20 | 0.430 |
Why?
|
| Lymph Nodes | 4 | 2022 | 548 | 0.430 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2013 | 47 | 0.430 |
Why?
|
| Mice | 32 | 2024 | 11737 | 0.430 |
Why?
|
| DNA-Binding Proteins | 7 | 2016 | 1241 | 0.420 |
Why?
|
| Immunophenotyping | 6 | 2021 | 217 | 0.420 |
Why?
|
| Apoptosis | 14 | 2016 | 1716 | 0.410 |
Why?
|
| Neutropenia | 1 | 2013 | 216 | 0.410 |
Why?
|
| Multiple Myeloma | 4 | 2022 | 330 | 0.410 |
Why?
|
| Fusion Proteins, bcr-abl | 4 | 2022 | 108 | 0.400 |
Why?
|
| Leukemia, Erythroblastic, Acute | 2 | 2022 | 30 | 0.400 |
Why?
|
| Aminopyridines | 2 | 2023 | 40 | 0.400 |
Why?
|
| Immunohistochemistry | 7 | 2022 | 1796 | 0.400 |
Why?
|
| Triazines | 2 | 2023 | 53 | 0.390 |
Why?
|
| Microtubule-Associated Proteins | 3 | 2010 | 184 | 0.390 |
Why?
|
| Bacterial Infections | 1 | 2013 | 184 | 0.380 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2012 | 54 | 0.380 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2022 | 2552 | 0.350 |
Why?
|
| Neoplasms, Second Primary | 3 | 2022 | 260 | 0.350 |
Why?
|
| Flavoproteins | 4 | 2003 | 25 | 0.340 |
Why?
|
| Animals | 39 | 2024 | 27317 | 0.340 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 5 | 2023 | 131 | 0.340 |
Why?
|
| RNA, Messenger | 5 | 2007 | 2011 | 0.340 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2019 | 1265 | 0.330 |
Why?
|
| Down-Regulation | 6 | 2022 | 519 | 0.330 |
Why?
|
| Transcription Factors | 8 | 2023 | 1652 | 0.320 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2021 | 159 | 0.310 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2016 | 665 | 0.310 |
Why?
|
| Membrane Proteins | 5 | 2016 | 1215 | 0.300 |
Why?
|
| WT1 Proteins | 1 | 2007 | 20 | 0.290 |
Why?
|
| CD36 Antigens | 1 | 2006 | 13 | 0.280 |
Why?
|
| GATA1 Transcription Factor | 6 | 2017 | 18 | 0.280 |
Why?
|
| Signal Transduction | 9 | 2022 | 3373 | 0.280 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2023 | 481 | 0.280 |
Why?
|
| Cell Transformation, Neoplastic | 6 | 2024 | 447 | 0.270 |
Why?
|
| Translocation, Genetic | 3 | 2016 | 266 | 0.270 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2007 | 111 | 0.270 |
Why?
|
| Biomarkers, Tumor | 3 | 2023 | 1543 | 0.260 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2016 | 126 | 0.260 |
Why?
|
| Disease Progression | 4 | 2024 | 1488 | 0.250 |
Why?
|
| Erythropoiesis | 2 | 2023 | 51 | 0.240 |
Why?
|
| Glutathione Transferase | 3 | 2003 | 112 | 0.240 |
Why?
|
| Gene Dosage | 3 | 2018 | 208 | 0.240 |
Why?
|
| Cell Self Renewal | 1 | 2024 | 20 | 0.240 |
Why?
|
| B-Lymphocytes | 1 | 2009 | 738 | 0.240 |
Why?
|
| Myelopoiesis | 2 | 2016 | 10 | 0.230 |
Why?
|
| Antibodies, Monoclonal | 4 | 2017 | 1400 | 0.230 |
Why?
|
| MDS1 and EVI1 Complex Locus Protein | 2 | 2021 | 6 | 0.230 |
Why?
|
| Chromosomes, Mammalian | 2 | 2021 | 36 | 0.230 |
Why?
|
| Male | 27 | 2024 | 42251 | 0.230 |
Why?
|
| Aniline Compounds | 1 | 2023 | 58 | 0.220 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2003 | 78 | 0.220 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2001 | 142 | 0.220 |
Why?
|
| Pyrazines | 1 | 2023 | 94 | 0.220 |
Why?
|
| Isoenzymes | 2 | 2001 | 274 | 0.220 |
Why?
|
| Extracellular Traps | 1 | 2022 | 11 | 0.220 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2014 | 616 | 0.210 |
Why?
|
| Calreticulin | 1 | 2022 | 13 | 0.210 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2022 | 20 | 0.210 |
Why?
|
| Chromosomes, Human, Pair 21 | 3 | 2015 | 54 | 0.210 |
Why?
|
| Germ Cells | 1 | 2023 | 130 | 0.210 |
Why?
|
| Mucin-4 | 1 | 2022 | 7 | 0.210 |
Why?
|
| Disease Susceptibility | 1 | 2023 | 200 | 0.210 |
Why?
|
| Retroviridae | 1 | 2022 | 79 | 0.200 |
Why?
|
| Unfolded Protein Response | 1 | 2022 | 43 | 0.200 |
Why?
|
| Stem Cells | 2 | 2019 | 372 | 0.200 |
Why?
|
| Thrombopoiesis | 2 | 2023 | 5 | 0.200 |
Why?
|
| Biomarkers | 3 | 2022 | 1755 | 0.200 |
Why?
|
| Child | 12 | 2018 | 7149 | 0.200 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2023 | 267 | 0.200 |
Why?
|
| Middle Aged | 15 | 2024 | 25863 | 0.200 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2014 | 307 | 0.200 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2024 | 412 | 0.190 |
Why?
|
| Peroxidase | 1 | 2021 | 51 | 0.190 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 582 | 0.190 |
Why?
|
| Female | 24 | 2024 | 46011 | 0.190 |
Why?
|
| Heat-Shock Proteins | 4 | 2003 | 183 | 0.190 |
Why?
|
| Adult | 17 | 2024 | 26507 | 0.190 |
Why?
|
| Epigenesis, Genetic | 3 | 2021 | 506 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 196 | 0.190 |
Why?
|
| Platelet Function Tests | 1 | 2020 | 11 | 0.190 |
Why?
|
| Colonic Neoplasms | 2 | 2004 | 573 | 0.190 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2021 | 64 | 0.180 |
Why?
|
| Carrier Proteins | 1 | 2024 | 681 | 0.180 |
Why?
|
| Cell Proliferation | 8 | 2024 | 1650 | 0.180 |
Why?
|
| World Health Organization | 2 | 2012 | 106 | 0.180 |
Why?
|
| Telomerase | 1 | 2020 | 62 | 0.180 |
Why?
|
| Prognosis | 6 | 2024 | 3773 | 0.180 |
Why?
|
| Aurora Kinase A | 2 | 2019 | 11 | 0.170 |
Why?
|
| Thrombosis | 1 | 2022 | 302 | 0.170 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2020 | 55 | 0.170 |
Why?
|
| Gene Expression Profiling | 6 | 2016 | 1429 | 0.170 |
Why?
|
| Cell Lineage | 5 | 2023 | 291 | 0.170 |
Why?
|
| DNA Repair | 1 | 2021 | 362 | 0.170 |
Why?
|
| Mice, Inbred C57BL | 8 | 2021 | 3209 | 0.170 |
Why?
|
| Loss of Function Mutation | 1 | 2019 | 46 | 0.170 |
Why?
|
| Gene Expression | 5 | 2008 | 1310 | 0.160 |
Why?
|
| GTPase-Activating Proteins | 1 | 2019 | 67 | 0.160 |
Why?
|
| Macrophages | 4 | 2010 | 571 | 0.160 |
Why?
|
| Adolescent | 11 | 2024 | 9237 | 0.160 |
Why?
|
| Histiocytosis, Sinus | 1 | 2018 | 15 | 0.160 |
Why?
|
| Cell Nucleus | 3 | 2014 | 599 | 0.160 |
Why?
|
| Genes, abl | 1 | 1998 | 12 | 0.150 |
Why?
|
| Influenza, Human | 1 | 2021 | 337 | 0.150 |
Why?
|
| Gene Expression Regulation | 2 | 2009 | 1975 | 0.150 |
Why?
|
| Cytogenetic Analysis | 2 | 2021 | 71 | 0.150 |
Why?
|
| Child, Preschool | 8 | 2017 | 3717 | 0.150 |
Why?
|
| Internship and Residency | 1 | 2007 | 1041 | 0.150 |
Why?
|
| Neoplasms | 3 | 2022 | 3035 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2023 | 604 | 0.150 |
Why?
|
| Parathyroid Neoplasms | 1 | 2017 | 57 | 0.150 |
Why?
|
| Flow Cytometry | 5 | 2016 | 691 | 0.140 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2017 | 103 | 0.140 |
Why?
|
| Immunoblotting | 4 | 2013 | 273 | 0.140 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2016 | 42 | 0.140 |
Why?
|
| Neoplasm, Residual | 2 | 2022 | 181 | 0.140 |
Why?
|
| Antibodies, Neoplasm | 2 | 2007 | 84 | 0.140 |
Why?
|
| Aged | 12 | 2024 | 19077 | 0.140 |
Why?
|
| Cell Differentiation | 6 | 2015 | 1521 | 0.140 |
Why?
|
| Recovery of Function | 1 | 2017 | 292 | 0.130 |
Why?
|
| Gene Fusion | 1 | 2016 | 39 | 0.130 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2007 | 142 | 0.130 |
Why?
|
| Chromosome Aberrations | 2 | 2014 | 390 | 0.130 |
Why?
|
| Mice, Knockout | 6 | 2024 | 1990 | 0.130 |
Why?
|
| Adenoma | 1 | 2017 | 246 | 0.130 |
Why?
|
| Green Fluorescent Proteins | 3 | 2005 | 309 | 0.130 |
Why?
|
| Granzymes | 1 | 2015 | 94 | 0.120 |
Why?
|
| Hodgkin Disease | 1 | 2016 | 181 | 0.120 |
Why?
|
| Pandemics | 1 | 2021 | 771 | 0.120 |
Why?
|
| Inflammation | 1 | 2020 | 971 | 0.120 |
Why?
|
| Young Adult | 7 | 2024 | 6288 | 0.120 |
Why?
|
| Chromosomal Instability | 1 | 2014 | 19 | 0.120 |
Why?
|
| Transfection | 6 | 2016 | 911 | 0.120 |
Why?
|
| Cyclin E | 1 | 2014 | 28 | 0.120 |
Why?
|
| Cell Line | 4 | 2016 | 2495 | 0.120 |
Why?
|
| F-Box Proteins | 1 | 2014 | 11 | 0.120 |
Why?
|
| Promyelocytic Leukemia Zinc Finger Protein | 1 | 2014 | 15 | 0.120 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 275 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 5 | 2016 | 921 | 0.120 |
Why?
|
| Genes, myc | 1 | 2014 | 39 | 0.120 |
Why?
|
| Mucous Membrane | 1 | 2014 | 83 | 0.120 |
Why?
|
| Myeloid Ecotropic Viral Integration Site 1 Protein | 4 | 2016 | 20 | 0.120 |
Why?
|
| Adenosine | 1 | 2016 | 237 | 0.120 |
Why?
|
| Tissue Array Analysis | 1 | 2014 | 127 | 0.120 |
Why?
|
| Granulocytes | 2 | 2010 | 38 | 0.110 |
Why?
|
| Disease Models, Animal | 6 | 2021 | 2362 | 0.110 |
Why?
|
| Neuroblastoma | 1 | 2017 | 394 | 0.110 |
Why?
|
| Disease-Free Survival | 3 | 2020 | 1214 | 0.110 |
Why?
|
| Doxorubicin | 4 | 2007 | 298 | 0.110 |
Why?
|
| Infant | 5 | 2017 | 3147 | 0.110 |
Why?
|
| Treatment Outcome | 6 | 2024 | 8203 | 0.110 |
Why?
|
| Killer Cells, Natural | 1 | 2015 | 275 | 0.110 |
Why?
|
| Stem Cell Factor | 1 | 2013 | 19 | 0.110 |
Why?
|
| Adenine Nucleotides | 1 | 2013 | 63 | 0.110 |
Why?
|
| Biopsy | 2 | 2014 | 1182 | 0.110 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2016 | 443 | 0.110 |
Why?
|
| Arabinonucleosides | 1 | 2013 | 39 | 0.110 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2014 | 170 | 0.110 |
Why?
|
| Stem Cell Niche | 1 | 2013 | 22 | 0.110 |
Why?
|
| Recombination, Genetic | 1 | 2015 | 444 | 0.110 |
Why?
|
| Vincristine | 3 | 2007 | 112 | 0.110 |
Why?
|
| Receptors, CXCR4 | 1 | 2013 | 45 | 0.110 |
Why?
|
| Retrospective Studies | 7 | 2024 | 9003 | 0.110 |
Why?
|
| Inhibitor of Apoptosis Proteins | 3 | 2010 | 33 | 0.110 |
Why?
|
| Cell Line, Tumor | 5 | 2016 | 2552 | 0.100 |
Why?
|
| Up-Regulation | 2 | 2016 | 727 | 0.100 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2014 | 387 | 0.100 |
Why?
|
| Lymphocyte Activation | 1 | 2015 | 751 | 0.100 |
Why?
|
| Immunotherapy | 1 | 2017 | 669 | 0.100 |
Why?
|
| Lymphocytes | 2 | 2008 | 471 | 0.100 |
Why?
|
| Cyclophosphamide | 3 | 2007 | 299 | 0.100 |
Why?
|
| Syndrome | 1 | 2013 | 449 | 0.100 |
Why?
|
| DNA, Complementary | 2 | 2003 | 392 | 0.100 |
Why?
|
| Janus Kinase 2 | 3 | 2019 | 60 | 0.100 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2012 | 76 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 340 | 0.100 |
Why?
|
| India | 4 | 2001 | 123 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2005 | 887 | 0.100 |
Why?
|
| Apoptosis Inducing Factor | 4 | 2003 | 6 | 0.100 |
Why?
|
| Hematologic Diseases | 2 | 2012 | 78 | 0.100 |
Why?
|
| Phenotype | 3 | 2022 | 2439 | 0.100 |
Why?
|
| Germ-Line Mutation | 1 | 2014 | 344 | 0.100 |
Why?
|
| Transplantation Conditioning | 1 | 2013 | 374 | 0.090 |
Why?
|
| Base Sequence | 4 | 2016 | 2327 | 0.090 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2010 | 13 | 0.090 |
Why?
|
| Bone Marrow Cells | 1 | 2012 | 262 | 0.090 |
Why?
|
| RNA-Binding Proteins | 1 | 2012 | 258 | 0.090 |
Why?
|
| T-Lymphocytes | 2 | 2014 | 1223 | 0.090 |
Why?
|
| Mi-2 Nucleosome Remodeling and Deacetylase Complex | 1 | 2009 | 5 | 0.090 |
Why?
|
| Glutathione S-Transferase pi | 2 | 2001 | 18 | 0.090 |
Why?
|
| Molecular Chaperones | 4 | 2003 | 122 | 0.090 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2010 | 24 | 0.090 |
Why?
|
| Multidrug Resistance-Associated Proteins | 2 | 2001 | 27 | 0.090 |
Why?
|
| Dura Mater | 1 | 2010 | 44 | 0.090 |
Why?
|
| Dexamethasone | 2 | 2022 | 344 | 0.090 |
Why?
|
| Fibrosis | 2 | 2022 | 234 | 0.090 |
Why?
|
| Erythroid-Specific DNA-Binding Factors | 3 | 2003 | 4 | 0.090 |
Why?
|
| Blotting, Western | 2 | 2015 | 794 | 0.090 |
Why?
|
| Herpesviridae | 1 | 2009 | 14 | 0.090 |
Why?
|
| Herpesvirus 8, Human | 1 | 2009 | 11 | 0.090 |
Why?
|
| Meningeal Neoplasms | 1 | 2010 | 65 | 0.090 |
Why?
|
| Mitochondria | 2 | 2003 | 553 | 0.080 |
Why?
|
| Recombinant Proteins | 3 | 2014 | 1012 | 0.080 |
Why?
|
| Autografts | 2 | 2020 | 28 | 0.080 |
Why?
|
| Colony-Forming Units Assay | 2 | 2007 | 40 | 0.080 |
Why?
|
| Mice, Transgenic | 3 | 2021 | 1574 | 0.080 |
Why?
|
| Spinal Cord Compression | 1 | 2008 | 27 | 0.080 |
Why?
|
| Cell Survival | 4 | 2016 | 982 | 0.080 |
Why?
|
| Gene Deletion | 2 | 2015 | 342 | 0.080 |
Why?
|
| Mutant Proteins | 2 | 2022 | 96 | 0.080 |
Why?
|
| Multipotent Stem Cells | 1 | 2008 | 19 | 0.080 |
Why?
|
| Lymphoid Progenitor Cells | 1 | 2008 | 16 | 0.080 |
Why?
|
| Spinal Neoplasms | 1 | 2008 | 48 | 0.080 |
Why?
|
| Sacrum | 1 | 2008 | 43 | 0.080 |
Why?
|
| Leukemia, Hairy Cell | 1 | 2008 | 186 | 0.080 |
Why?
|
| Homeostasis | 1 | 2010 | 413 | 0.080 |
Why?
|
| Lymphopoiesis | 1 | 2008 | 48 | 0.080 |
Why?
|
| Proto-Oncogenes | 2 | 2013 | 61 | 0.080 |
Why?
|
| Aged, 80 and over | 4 | 2024 | 6777 | 0.080 |
Why?
|
| Transcription, Genetic | 4 | 2016 | 1157 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 2411 | 0.080 |
Why?
|
| Trisomy | 1 | 2007 | 55 | 0.070 |
Why?
|
| Protein Binding | 2 | 2019 | 1487 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2014 | 2335 | 0.070 |
Why?
|
| Lumbar Vertebrae | 1 | 2008 | 151 | 0.070 |
Why?
|
| Prednisolone | 1 | 2007 | 40 | 0.070 |
Why?
|
| Bone Marrow Transplantation | 3 | 2016 | 283 | 0.070 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2008 | 170 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2007 | 77 | 0.070 |
Why?
|
| Precipitin Tests | 2 | 2003 | 111 | 0.070 |
Why?
|
| Neoplasm Staging | 2 | 2015 | 2001 | 0.070 |
Why?
|
| Rare Diseases | 1 | 2007 | 65 | 0.070 |
Why?
|
| Rituximab | 1 | 2007 | 119 | 0.070 |
Why?
|
| Phosphorylation | 3 | 2019 | 1130 | 0.070 |
Why?
|
| Biopsy, Needle | 1 | 2007 | 233 | 0.070 |
Why?
|
| Luminescent Proteins | 2 | 2003 | 144 | 0.070 |
Why?
|
| Spleen | 3 | 2013 | 432 | 0.070 |
Why?
|
| Cells, Cultured | 3 | 2009 | 2880 | 0.070 |
Why?
|
| Genomics | 2 | 2022 | 761 | 0.070 |
Why?
|
| Mutagenesis | 2 | 2003 | 202 | 0.070 |
Why?
|
| Cytosol | 2 | 2003 | 193 | 0.070 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2007 | 157 | 0.070 |
Why?
|
| Lung | 2 | 2022 | 1258 | 0.060 |
Why?
|
| Age Factors | 2 | 2001 | 1867 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 2 | 2003 | 740 | 0.060 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 1998 | 261 | 0.060 |
Why?
|
| Remission Induction | 2 | 2012 | 740 | 0.060 |
Why?
|
| Preleukemia | 1 | 2024 | 11 | 0.060 |
Why?
|
| Cytochrome c Group | 2 | 2003 | 83 | 0.060 |
Why?
|
| Cytochromes c | 1 | 2004 | 27 | 0.060 |
Why?
|
| Mixed Function Oxygenases | 2 | 2016 | 69 | 0.060 |
Why?
|
| Cloning, Molecular | 1 | 2005 | 646 | 0.060 |
Why?
|
| Acute Disease | 3 | 2016 | 841 | 0.060 |
Why?
|
| Cell Movement | 2 | 2019 | 783 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2022 | 967 | 0.060 |
Why?
|
| Drug Resistance, Multiple | 2 | 2001 | 20 | 0.060 |
Why?
|
| Rats | 4 | 2004 | 4040 | 0.060 |
Why?
|
| Subcellular Fractions | 1 | 2003 | 94 | 0.060 |
Why?
|
| I-kappa B Proteins | 1 | 2003 | 54 | 0.060 |
Why?
|
| Models, Genetic | 2 | 2012 | 944 | 0.060 |
Why?
|
| Multienzyme Complexes | 1 | 2003 | 65 | 0.060 |
Why?
|
| Quantitative Trait Loci | 1 | 2007 | 607 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2003 | 100 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2003 | 1057 | 0.060 |
Why?
|
| Peptide Hydrolases | 1 | 2003 | 101 | 0.050 |
Why?
|
| Cysteine Endopeptidases | 1 | 2003 | 88 | 0.050 |
Why?
|
| In Situ Hybridization | 2 | 2021 | 313 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1363 | 0.050 |
Why?
|
| Interleukin-13 | 1 | 2022 | 38 | 0.050 |
Why?
|
| Cytoplasm | 1 | 2003 | 284 | 0.050 |
Why?
|
| Imides | 1 | 2022 | 26 | 0.050 |
Why?
|
| Precancerous Conditions | 1 | 2024 | 200 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 95 | 0.050 |
Why?
|
| X-Box Binding Protein 1 | 1 | 2022 | 16 | 0.050 |
Why?
|
| Philadelphia Chromosome | 1 | 2022 | 41 | 0.050 |
Why?
|
| Retreatment | 1 | 2022 | 108 | 0.050 |
Why?
|
| Proteasome Inhibitors | 1 | 2022 | 52 | 0.050 |
Why?
|
| Curriculum | 1 | 2007 | 567 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2023 | 274 | 0.050 |
Why?
|
| Interleukin-4 | 1 | 2022 | 130 | 0.050 |
Why?
|
| Abnormal Karyotype | 1 | 2022 | 8 | 0.050 |
Why?
|
| Time Factors | 3 | 2016 | 5320 | 0.050 |
Why?
|
| Karyotype | 1 | 2022 | 34 | 0.050 |
Why?
|
| DNA Mutational Analysis | 3 | 2014 | 529 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 1 | 2003 | 428 | 0.050 |
Why?
|
| Protein Transport | 1 | 2003 | 421 | 0.050 |
Why?
|
| Cell-Free System | 1 | 2001 | 51 | 0.050 |
Why?
|
| Models, Biological | 4 | 2019 | 1763 | 0.050 |
Why?
|
| Amino Acid Sequence | 2 | 2016 | 2062 | 0.050 |
Why?
|
| Endoribonucleases | 1 | 2022 | 92 | 0.050 |
Why?
|
| Transcriptome | 2 | 2016 | 628 | 0.050 |
Why?
|
| Symbiosis | 1 | 2022 | 126 | 0.050 |
Why?
|
| Plasmids | 1 | 2001 | 291 | 0.050 |
Why?
|
| Autopsy | 1 | 2021 | 122 | 0.050 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2000 | 16 | 0.050 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2000 | 20 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2023 | 645 | 0.050 |
Why?
|
| Carcinogenesis | 1 | 2022 | 211 | 0.050 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 2000 | 37 | 0.050 |
Why?
|
| Biology | 1 | 2020 | 52 | 0.050 |
Why?
|
| Chromosome Mapping | 1 | 2003 | 1076 | 0.040 |
Why?
|
| Risk | 2 | 2012 | 657 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2013 | 4273 | 0.040 |
Why?
|
| Cell Division | 1 | 2001 | 696 | 0.040 |
Why?
|
| Transplantation, Homologous | 2 | 2013 | 995 | 0.040 |
Why?
|
| Peptides | 1 | 2003 | 646 | 0.040 |
Why?
|
| Neoplasms, Experimental | 1 | 2001 | 269 | 0.040 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2001 | 189 | 0.040 |
Why?
|
| Telomere | 1 | 2020 | 114 | 0.040 |
Why?
|
| Seasons | 1 | 2021 | 237 | 0.040 |
Why?
|
| Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases | 1 | 2019 | 4 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2020 | 354 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2019 | 13 | 0.040 |
Why?
|
| Oligopeptides | 1 | 2020 | 188 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2007 | 2290 | 0.040 |
Why?
|
| Genes, MDR | 1 | 1998 | 7 | 0.040 |
Why?
|
| Bacteria | 1 | 2022 | 472 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2001 | 755 | 0.040 |
Why?
|
| Myeloid Progenitor Cells | 2 | 2008 | 16 | 0.040 |
Why?
|
| Caspases | 3 | 2003 | 155 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 1998 | 223 | 0.040 |
Why?
|
| Calcium | 1 | 2022 | 1172 | 0.040 |
Why?
|
| Hepatitis B | 1 | 1998 | 75 | 0.040 |
Why?
|
| Cellular Senescence | 1 | 2018 | 103 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 247 | 0.040 |
Why?
|
| Retinoic Acid Receptor alpha | 1 | 2016 | 18 | 0.040 |
Why?
|
| Plasma Cells | 1 | 2017 | 84 | 0.040 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2016 | 20 | 0.040 |
Why?
|
| Chromosome Breakpoints | 1 | 2016 | 15 | 0.040 |
Why?
|
| DNA Methylation | 2 | 2012 | 657 | 0.040 |
Why?
|
| Ribosomal Proteins | 1 | 2017 | 45 | 0.040 |
Why?
|
| Anemia | 1 | 2018 | 129 | 0.040 |
Why?
|
| Alemtuzumab | 2 | 2007 | 85 | 0.040 |
Why?
|
| DNA | 1 | 2022 | 1307 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2017 | 109 | 0.040 |
Why?
|
| Prevalence | 1 | 2020 | 1240 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2017 | 229 | 0.030 |
Why?
|
| Tretinoin | 1 | 2016 | 128 | 0.030 |
Why?
|
| Prednisone | 2 | 2007 | 258 | 0.030 |
Why?
|
| Fatal Outcome | 2 | 2007 | 299 | 0.030 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2015 | 4 | 0.030 |
Why?
|
| Polyploidy | 1 | 2015 | 18 | 0.030 |
Why?
|
| Proteins | 1 | 2001 | 786 | 0.030 |
Why?
|
| Azepines | 1 | 2015 | 25 | 0.030 |
Why?
|
| Hepatitis C | 1 | 1998 | 170 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2015 | 64 | 0.030 |
Why?
|
| Methylation | 1 | 2016 | 268 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2016 | 94 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2015 | 85 | 0.030 |
Why?
|
| I-kappa B Kinase | 1 | 2015 | 41 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 2015 | 159 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2016 | 426 | 0.030 |
Why?
|
| Nitriles | 1 | 2015 | 160 | 0.030 |
Why?
|
| Integrases | 1 | 2015 | 62 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2015 | 306 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 232 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2015 | 147 | 0.030 |
Why?
|
| Sex Factors | 1 | 1998 | 1063 | 0.030 |
Why?
|
| Nanoparticles | 1 | 2016 | 164 | 0.030 |
Why?
|
| Positron-Emission Tomography | 2 | 2007 | 336 | 0.030 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2014 | 4 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2015 | 150 | 0.030 |
Why?
|
| Transgenes | 1 | 2015 | 185 | 0.030 |
Why?
|
| Heterozygote | 1 | 2015 | 373 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2016 | 217 | 0.030 |
Why?
|
| Protein Stability | 1 | 2014 | 100 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2012 | 1940 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2014 | 109 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2016 | 638 | 0.030 |
Why?
|
| Proteolysis | 1 | 2014 | 108 | 0.030 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2013 | 31 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2013 | 96 | 0.030 |
Why?
|
| Etoposide | 2 | 2004 | 198 | 0.030 |
Why?
|
| Chromatin | 2 | 2009 | 397 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2014 | 181 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2014 | 338 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2013 | 136 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2013 | 66 | 0.030 |
Why?
|
| Binding Sites | 1 | 2016 | 1117 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2013 | 106 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2015 | 372 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2012 | 37 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2013 | 104 | 0.030 |
Why?
|
| Cytosine | 1 | 2013 | 128 | 0.030 |
Why?
|
| Thrombocytosis | 1 | 2012 | 8 | 0.030 |
Why?
|
| U937 Cells | 2 | 2003 | 32 | 0.030 |
Why?
|
| Calcineurin | 1 | 2012 | 20 | 0.030 |
Why?
|
| 5-Methylcytosine | 1 | 2013 | 117 | 0.030 |
Why?
|
| HSP27 Heat-Shock Proteins | 2 | 2003 | 33 | 0.030 |
Why?
|
| Pedigree | 1 | 2014 | 969 | 0.030 |
Why?
|
| Mitoxantrone | 1 | 2012 | 68 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 1591 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2013 | 244 | 0.020 |
Why?
|
| Cytarabine | 1 | 2012 | 219 | 0.020 |
Why?
|
| Survival Rate | 1 | 2015 | 1889 | 0.020 |
Why?
|
| United States | 1 | 2024 | 6955 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 695 | 0.020 |
Why?
|
| Diarrhea | 1 | 2012 | 182 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 294 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 188 | 0.020 |
Why?
|
| GATA2 Transcription Factor | 1 | 2009 | 14 | 0.020 |
Why?
|
| Erythroid Cells | 1 | 2009 | 14 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 859 | 0.020 |
Why?
|
| Genotype | 2 | 2007 | 1848 | 0.020 |
Why?
|
| Recurrence | 1 | 2012 | 1140 | 0.020 |
Why?
|
| Liver | 1 | 2013 | 1205 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 1710 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2010 | 1087 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2012 | 1855 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 3027 | 0.020 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2007 | 57 | 0.020 |
Why?
|
| Oncogene Proteins | 1 | 2007 | 61 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2007 | 231 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 956 | 0.020 |
Why?
|
| Radiography | 1 | 2008 | 809 | 0.020 |
Why?
|
| Exons | 1 | 2007 | 451 | 0.020 |
Why?
|
| Incidence | 2 | 2001 | 1592 | 0.020 |
Why?
|
| DNA, Antisense | 1 | 2004 | 15 | 0.010 |
Why?
|
| HT29 Cells | 1 | 2004 | 50 | 0.010 |
Why?
|
| Staurosporine | 1 | 2004 | 33 | 0.010 |
Why?
|
| Peptide Mapping | 1 | 2003 | 26 | 0.010 |
Why?
|
| Caspase 9 | 1 | 2003 | 49 | 0.010 |
Why?
|
| HCT116 Cells | 1 | 2004 | 155 | 0.010 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2003 | 42 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 2003 | 103 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2003 | 162 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2003 | 72 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2011 | 1670 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2003 | 106 | 0.010 |
Why?
|
| Ubiquitin | 1 | 2003 | 96 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2003 | 275 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 2399 | 0.010 |
Why?
|
| Cell Death | 1 | 2003 | 262 | 0.010 |
Why?
|
| Apoptotic Protease-Activating Factor 1 | 1 | 2001 | 7 | 0.010 |
Why?
|
| Chaperonin 60 | 1 | 2001 | 7 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 2001 | 21 | 0.010 |
Why?
|
| CD8 Antigens | 1 | 2001 | 82 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2003 | 446 | 0.010 |
Why?
|
| Cisplatin | 1 | 2004 | 617 | 0.010 |
Why?
|
| CD4 Antigens | 1 | 2001 | 83 | 0.010 |
Why?
|
| Macrophage Activation | 1 | 2001 | 49 | 0.010 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2001 | 47 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2003 | 887 | 0.010 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2001 | 131 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2001 | 293 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2003 | 465 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 699 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 2000 | 144 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 2001 | 229 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2001 | 451 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2003 | 1296 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2003 | 1097 | 0.010 |
Why?
|
| Research | 1 | 2000 | 252 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2000 | 698 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2003 | 2476 | 0.010 |
Why?
|